20:54 , Dec 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neuropathy Mouse and rat studies suggest inhibiting PMP22 could help treat Charcot-Marie-Tooth 1A (CMT1A) disease. In a mouse model of CMT1A, subcutaneous injection of an antisense oligonucleotide (ASO) targeting PMP22 increased motor nerve conduction velocity,...
07:00 , Oct 17, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Markers

This week in techniques Approach Summary Licensing status Publication and contact information Markers Three-gene signature predictive of indolent prostate cancer A three-gene signature could help identify patients who...
08:00 , Jan 21, 2013 |  BC Week In Review  |  Clinical News

Addex preclinical data

In a rat model of CMT1A, 10 mg/kg oral ADX71441 given every other day for 5 weeks followed by once-daily 5 mg/kg ADX71441 for 4 weeks down regulated PMP22 mRNA, reduced the number of hypo-myelinated...